Drug intelligence / Profile preview

KMR301

Development stage: Preclinical
Lead developer: TrialSpark
Modality: Small Molecules
Administration: Oral

Overview

KMR301 (also known as FHND5032) is an oral, small-molecule inducer of microRNA-124 (miR-124) currently in preclinical development for the treatment of autoimmune and inflammatory diseases. Originally developed by Jiangsu Chia Tai Feng Hai Pharmaceutical (CTFH), the asset was acquired by Formation Bio (formerly TrialSpark) and is being progressed through its subsidiary, Kenmare Bio. miR-124 is an anti-inflammatory microRNA that is typically downregulated in various chronic inflammatory conditions, including ulcerative colitis. By inducing the expression or activity of miR-124, KMR301 aims to restore homeostatic immune regulation and reduce inflammation. The drug has demonstrated efficacy in preclinical models of ulcerative colitis and is scheduled to enter clinical trials in 2026.

Other names: FHND5032FHND-5032FHND 5032

Beyond the preview

Go deeper on KMR301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KMR301.

Explore the full profile